PTC Therapeutics announces the launch of the sixth annual STRIVE grant awards program for Duchenne muscular dystrophy.

The STRIVE Awards provide a grant to patient advocacy organizations to develop programs that make meaningful contributions to those in the rare disease community.

The deadline for submissions is Thursday, April 30. Winners will be announced later this year on World Duchenne Awareness Day, according to a media release.

“The funding we received from the STRIVE Award last year has been fundamental in supporting our mission to acquire life-saving medical equipment, allowing us to deliver medical care and emotional support for those affected by Duchenne in northern Mexico,” says Graciela Méndez Covarrubias, ENLACE, in the release.

Since its launch in 2015, the STRIVE program has supported almost 30 patient programs dedicated to improving the lives of those affected by Duchenne, even in the most remote locations around the world. Previous winning programs have improved access to diagnosis and treatment, provided emotional support for families, and developed opportunities for personal empowerment and independent living for those with Duchenne.

“After celebrating the five-year milestone of the STRIVE Awards in 2019, we continue to be hugely proud of helping patient organizations from around the world provide vital support to the Duchenne community by bringing novel and pioneering projects to life,” states Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics.

“We know that the advocacy organizations supporting the Duchenne community still have so many more inspiring and creative initiatives, and we are as excited as ever to see the proposals that will be submitted this year.”

For more information around the criteria for applications, selection process and how to apply, visit PTC Therapeutics.

[Source(s): PTC Therapeutics, PR Newswire]